bioMérieux S.A. (BMXXY) Research

bioMérieux S.A. is a global leader in the development and production of in vitro diagnostic solutions, primarily aimed at detecting infectious diseases. Its operations span the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. The company provides sophisticated diagnostic platforms that analyze biological specimens to pinpoint infectious diseases, cardiovascular conditions, and various cancers. Additionally, it offers microbiological testing for quality control in manufacturing, serving the food, pharmaceutical, cosmetics, and veterinary industries. Its diverse clientele encompasses clinical and hospital laboratories, medical practitioners, blood banks, and industrial control facilities. Founded in 1963, the company, previously known as B-D Mérieux, maintains its headquarters in Marcy l'Etoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.

Market snapshot

Symbol
BMXXY
Price
$7.25
Day change
-8.81%
Market cap
$8.1B
P/E ratio
20.47x
52-week range
7.25-14.62
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • Astellas Pharma Inc. (ALPMY)
  • Grifols, S.A. (GIKLY)
  • Genmab A/S (GNMSF)
  • Orion Oyj (ORINY)
  • Straumann Holding AG (SAUHF)
  • Straumann Holding AG (SAUHY)
  • Sino Biopharmaceutical Limited (SBHMY)
  • Smith & Nephew plc (SNNUF)

Open bioMérieux S.A. (BMXXY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.